

Community Practice Considerations: Emerging Bispecific Antibodies in NHL

Resource	Address
Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's lymphoma classification project. <i>J Clin Oncol</i> . 1998;16:2780-2795. doi:10.1200/JCO.1998.16.8.2780	https://pubmed.ncbi.nlm.nih.gov/9704731/
Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: Moving toward a molecularly targeted approach. <i>Blood</i> . 2005;106:1164-1174. doi:10.1182/blood-2005-02-0687	https://pubmed.ncbi.nlm.nih.gov/15855278/
Bannerji R, Allan JN, Arnason JE, et al. Odronextamab (REGN1979), a human CD20 x CD3 bispecific antibody, induces durable, complete responses in patients with highly refractory B-cell non-Hodgkin lymphoma, including patients refractory to CAR T therapy. <i>Blood</i> . 2020;136(suppl 1):42-43. doi:10.1182/blood-2020-136659	https://www.sciencedirect.com/science/article/pii/S0006497118696065
Bannerji R, Arnason JE, Advani RH, et al. Odronextamab, a human CD20 x CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): Results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. <i>Lancet Haematol</i> . 2022;9:e327-e339.	https://pubmed.ncbi.nlm.nih.gov/35366963/
Bartlett NL, Giri P, Budde LE, et al. Subcutaneous (SC) administration of mosunetuzumab with cycle 1 step-up dosing is tolerable and active in patients with relapsed/refractory B-cell non-Hodgkin lymphomas (R/R B-NHL): Initial results from a phase I/II study. <i>Blood</i> . 2021;138(suppl 1):3573. doi:10.1182/blood-2021-147937	https://www.sciencedirect.com/science/article/pii/S0006497121054975
Bishop MR, Dickinson M, Purtil D, et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. <i>N Engl J Med</i> . 2022;386:629-639. doi:10.1056/nejmoa2116596	https://pubmed.ncbi.nlm.nih.gov/34904798/
Budde LE, Assouline S, Sehn LH, et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: Phase I dose-escalation study. <i>J Clin Oncol</i> . 2022;40:481-491. doi:10.1200/jco.21.00931	https://pubmed.ncbi.nlm.nih.gov/34914545/
Cahill KE, Smith SM. Follicular lymphoma: A focus on current and emerging therapies. <i>Oncology (Williston Park)</i> . 2022;36:97-106. doi:10.46883/2022.25920946	https://pubmed.ncbi.nlm.nih.gov/35180337/
Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicenter, open-label, single-arm, phase 2 trial. <i>Lancet Oncol</i> . 2021;22:790-800. doi:10.1016/S1470-2045(21)00139-X	https://pubmed.ncbi.nlm.nih.gov/33989558/

<p>Carbone A, Roulland S, Gloghini A, et al. Follicular lymphoma. <i>Nat Rev Dis Primers</i>. 2019;5:83. doi:10.1038/s42572-019-0132-x</p>	<p>https://pubmed.ncbi.nlm.nih.gov/31831752/</p>
<p>Casulo C. Follicular lymphoma: Is there an optimal way to define risk? <i>Hematology Am Soc Hematol Educ Program</i>. 2021;2021:313-319. doi:10.1182/hematology.2021000264</p>	<p>https://pubmed.ncbi.nlm.nih.gov/34889370/</p>
<p>Cerhan JR. Epidemiology of follicular lymphoma. <i>Hematol Oncol Clin North Am</i>. 2020;34:631-646. doi:10.1016/j.hoc.2020.02.001</p>	<p>https://pubmed.ncbi.nlm.nih.gov/32586570/</p>
<p>Diamond B, Kumar A. Mantle cell lymphoma: Current and emerging treatment strategies and unanswered questions. <i>Hematol Oncol Clin North Am</i>. 2019;33:613-626. doi:10.1016/j.hoc.2019.03.002</p>	<p>https://pubmed.ncbi.nlm.nih.gov/31229158/</p>
<p>Dickinson M, Carto-Stella C, Morschhauser F, et al. Glofitamab induces durable complete remissions and has favorable safety in patients with relapsed/refractory diffuse large B-cell lymphoma and ≥2 prior therapies: Pivotal phase II expansion results. Presented at: European Hematology Association Annual Meeting (EHA 2022). 2022. Abstract S220.</p>	<p>https://library.ehaweb.org/eha/2022/eha2022-congress/357084/michael.dickinson.glofitamab.induces.durable.complete.remissions.and.has.html</p>
<p>Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab monotherapy provides durable responses after fixed-length dosing in relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (pts). <i>Blood</i>. 2021;138(suppl 1):2478. doi:10.1182/blood-2021-146845</p>	<p>https://ashpublications.org/blood/article/138/Supplement%201/2478/478856/Glofitamab-Monotherapy-Provides-Durable-Responses</p>
<p>Duell J, Maddocks KJ, Gonzalez-Barca E, et al. Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. <i>Haematologica</i>. 2021;106:2417-2426. doi:10.3324/haematol.2020.275958</p>	<p>https://pubmed.ncbi.nlm.nih.gov/34196165/</p>
<p>Essa H, Lodhi T, Dobson R, Wright D, Lip GYH. How to manage atrial fibrillation secondary to Ibrutinib. <i>JACC CardioOncol</i>. 2021;3:140-144. doi:10.1016/j.jacc.2020.11.016</p>	<p>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352308/</p>
<p>Eyre TA, Savage KJ, Cheah CY, et al. CNS prophylaxis for diffuse large B-cell lymphoma. <i>Lancet Oncol</i>. 2022;23:e416-e426. doi:10.1016/S1470-2045(22)00371-0</p>	<p>https://pubmed.ncbi.nlm.nih.gov/36055310/</p>
<p>Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: A new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. <i>J Clin Oncol</i>. 2009;27:4555-4562. doi:10.1200/JCO.2008.21.3991</p>	<p>https://pubmed.ncbi.nlm.nih.gov/19652063/</p>
<p>Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. <i>J Clin Oncol</i>. 2005;23:4117-4126. doi:10.1200/JCO.2005.09.131</p>	<p>https://pubmed.ncbi.nlm.nih.gov/15867204/</p>

<p>Fowler NH, Dickinson M, Dreyling M, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. <i>Nat Med</i>. 2022;28:325-332. doi:10.1038/s41591-021-01622-0</p>	<p>https://pubmed.ncbi.nlm.nih.gov/34921238/</p>
<p>Hosseini I, Gadkar K, Stefanich E, et al. Mitigating the risk of cytokine release syndrome in a phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: Impact of translational system modeling. <i>NPJ Syst Biol Appi</i>. 2020;6:28. doi:10.1038/s41540-020-00145-7</p>	<p>https://pubmed.ncbi.nlm.nih.gov/32859946/</p>
<p>Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. <i>Blood</i>. 2008;111:558-565. doi:10.1182/blood-2007-06-095331</p>	<p>https://pubmed.ncbi.nlm.nih.gov/17962512/</p>
<p>Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: An open-label, phase 1/2 study. <i>Lancet</i>. 2021;398:1157-1169. doi:10.1016/s0140-6736(21)00889-8</p>	<p>https://pubmed.ncbi.nlm.nih.gov/34508654/</p>
<p>Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicenter, phase 2 trial. <i>Lancet Oncol</i>. 2022;23:91-103. doi:10.1016/S1470-2045(21)00591-X</p>	<p>https://pubmed.ncbi.nlm.nih.gov/34895487/</p>
<p>Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. <i>Blood</i>. 2015;125:1394-1402. doi:10.1182/blood-2014-09-598763</p>	<p>https://pubmed.ncbi.nlm.nih.gov/25573987/</p>
<p>Kamdar M, Solomon SR, Arnason JE, et al. Lisocabtagene maraleucel (iiso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Results from the randomized phase 3 transform study. <i>Blood</i>. 2021;138(suppl 1):91-94. doi:10.1182/blood-2021-147913</p>	<p>https://www.sciencedirect.com/science/article/pii/S0006497121020814</p>
<p>Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: A phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. <i>J Clin Oncol</i>. 2019;37:1188-1199. doi:10.1200/JCO.19.00010</p>	<p>https://pubmed.ncbi.nlm.nih.gov/30897038/</p>
<p>Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. <i>N Engl J Med</i>. 2022;386:640-654. doi:10.1056/NEJMoa2116133</p>	<p>https://pubmed.ncbi.nlm.nih.gov/34891224/</p>
<p>Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. <i>N Engl J Med</i>. 2017;377:1331-1344. doi:10.1056/NEJMoa1614598</p>	<p>https://pubmed.ncbi.nlm.nih.gov/28976863/</p>

<p>Minson A, Dickinson M. Glofitamab CD20-TCB bispecific antibody. <i>Lymphoma</i>. 2021;62:3098-3108. doi:10.1080/10428194.2021.1953016</p>	<p>https://pubmed.ncbi.nlm.nih.gov/34263696/</p>
<p>National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology. B-Cell Lymphomas. V5.2022. July 12, 2022.</p>	<p>www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf</p>
<p>Sehn LH, Herrera AF, Flowers CR, et al. polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. <i>J Clin Oncol</i>. 2020;38:155-165. doi:10.1200/jco.19.00172</p>	<p>https://pubmed.ncbi.nlm.nih.gov/31693429/</p>
<p>Song Y, Zhou K, Zou D, et al. Zanubrutinib in relapsed/refractory mantle cell lymphoma: Long-term efficacy and safety results from a phase 2 study. <i>Blood</i>. 2022;139:3148-3158. doi:10.1182/blood.2021014162</p>	<p>https://pubmed.ncbi.nlm.nih.gov/35303070/</p>
<p>Thieblemont C, Phillips T, Ghesquieres H, et al. Primary results of subcutaneous epcoritamab dose expansion in patients with relapsed or refractory large B-cell lymphoma: A phase 2 study. Presented at: European Hematology Association Annual Meeting (EHA 2022). 2022. Abstract LB2364.</p>	<p>https://library.ehaweb.org/eha/2022/eha2022-congress/366208/catherine.thieblemont.primary.results.of.subcutaneous.epcoritamab.dose.html</p>
<p>Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. <i>N Engl J Med</i>. 2022;386:351-363. doi:10.1056/nejmoa2115304</p>	<p>https://pubmed.ncbi.nlm.nih.gov/34904799/</p>
<p>Vitolo U, Trněný M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. <i>J Clin Oncol</i>. 2017;35:3529-3537. doi:10.1200/JCO.2017.73.3402</p>	<p>https://pubmed.ncbi.nlm.nih.gov/28796588/</p>
<p>Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results. <i>Blood</i>. 2015;126:739-745. doi:10.1182/blood-2015-03-635326</p>	<p>https://pubmed.ncbi.nlm.nih.gov/26059948/</p>
<p>Wang M, Munoz J, Goy A, et al. Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. <i>J Clin Oncol</i>. 2022;JCO2102370. doi:10.1200/JCO.21.02370</p>	<p>https://pubmed.ncbi.nlm.nih.gov/35658525/</p>
<p>Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): A single-arm, multicenter, phase 2 trial. <i>Lancet</i>. 2018;391:659-667. doi:10.1016/S0140-6736(17)33108-2</p>	<p>https://pubmed.ncbi.nlm.nih.gov/29241979/</p>
<p>Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle cell lymphoma. <i>N Engl J Med</i>. 2020;382:1331-1342. doi:10.1056/NEJMoa1914347</p>	<p>https://pubmed.ncbi.nlm.nih.gov/32242358/</p>

Wang M, Rule S, Zinzani PL, et al. Acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma: Final results from a phase 2 study. Poster Presented at the Pan Pacific Lymphoma Conference; August 9-13, 2021; Waimea, Hawaii.	https://42bc4161a075f7e50e6f-a3bc3137033c5da42be80ce1198f9076.ssl.cf1.rackcdn.com/1696067-1626364181.pdf
Wasilewski A, Mohile N. Meet the expert: How I treat chemotherapy-induced peripheral neuropathy. <i>J Geriatr Oncol.</i> 2021;12:1-5. doi:10.1016/j.jgo.2020.06.008	https://pubmed.ncbi.nlm.nih.gov/32561202/
Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. <i>Blood.</i> 2014;123:837-842. doi:10.1182/blood-2013-09-524108	https://pubmed.ncbi.nlm.nih.gov/24264230/
Zhu M, Olson K, Kirshner JR, et al. Translational findings for odronextamab: From preclinical research to a first-in-human study in patients with CD20+ B-cell malignancies. <i>Clin Transl Sci.</i> 2022;15:954-966. doi:10.1111/cts.13212	https://pubmed.ncbi.nlm.nih.gov/34997701/

Resources and Societies

Resource	Address
American Cancer Society (ACS). What is Non-Hodgkin Lymphoma.	https://www.cancer.org/cancer/non-hodgkin-lymphoma/about/what-is-non-hodgkin-lymphoma.html
Leukemia and Lymphoma Society (LLS). Non-Hodgkin Lymphoma.	https://www.lls.org/lymphoma/non-hodgkin-lymphoma
National Cancer Institute (NCI). Adult Non-Hodgkin Lymphoma Treatment (PDQ®)—Patient Version. Updated August 31, 2022.	https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq
National Comprehensive Cancer Network® (NCCN)	https://www.nccn.org/home